Patent application number | Description | Published |
20090187182 | RF ABLATION DEVICE WITH JAM-PREVENTING ELECTRICAL COUPLING MEMBER - The inventive ablation element comprises an elongated cannula having a proximal end and a distal end. The cannula defines an internal lumen within the cannula and a cannula axis. A plurality of conductors contained within the lumen, each of the conductors has a proximal end proximate the proximal end of the cannula, and a distal end proximate the distal end of the cannula. A plurality of ablation stylets each has a proximal end and a distal end, and each coupled at the respective proximal end of the stylet to the distal end of a respective conductor, the stylets comprise a deflectable material, the conductors together with their respective stylets being mounted for axial movement. A trocar point defined proximate the distal end of the cannula. A deflection surface positioned between the trocar point and the proximal end of the cannula, the deflection surface being configured and positioned to deflect, in response to axial movement of the stylets in a direction from the proximate end of the cannula to the distal end of the cannula, at least some of the stylets laterally with respect to the cannula axis in different directions along substantially straight paths, the paths defining an ablation volume. | 07-23-2009 |
20110230874 | ABLATION METHOD - A method of ablating a uterine fibroid using a particular trocar is disclosed. The trocar comprises a plurality of ablation stylets mounted for movement from within the trocar to positions extending from the trocar. The trocar is adjustable to assume a plurality of configurations, each of the configurations having the stylets extended to a different extent from the trocar. A region to be ablated is imaged. The region may correspond to all or a portion of a uterine fibroid. The size of the region to be ablated is noted. The size of the region to be ablated is compared to a matrix of known ablation regions, each of the known ablation regions being associated with one of the configurations of the particular trocar, and each of the known ablation regions being associated with a position of the trocar relative to the known ablation region. The region to be ablated is associated with a most nearly matching known ablation region by comparison of the region to be ablated to the known ablation regions. A trocar of the design of the particular trocar is inserted into the uterine fibroid at a position, with respect to the region to be ablated, which more closely matches the position of the particular trocar with respect to the known ablation region. The stylets are deployed from the trocar to an extent corresponding to the configuration associated with the most nearly matching known ablation region. | 09-22-2011 |
20150066003 | Anchored RF Ablation Device for The Destruction of Tissue Masses - The inventive ablation element comprises an elongated cannula having a proximal end and a distal end. The cannula defines an internal lumen and a cannula axis. A plurality of conductors contained within the lumen, each having a proximal end proximate the proximal end of the cannula, and a distal end proximate the distal end of the cannula. A plurality of ablation stylets each has a proximal end and a distal end, and each coupled to the distal end of a respective conductor, the conductors together with their respective stylets being mounted for axial movement. A trocar point defined proximate the distal end of the cannula. A deflection surface positioned between the trocar point and the proximal end of the cannula, the deflection surface being configured and positioned to deflect at least some of the stylets laterally with respect to the cannula axis in different directions defining an ablation volume. | 03-05-2015 |
20150066020 | ABLATION METHOD - A method of ablating a uterine fibroid using a particular trocar is disclosed. The trocar comprises a plurality of ablation stylets. The trocar is adjustable to assume a plurality of configurations, each of the configurations having the stylets extended to a different extent from the trocar. A region to he ablated is imaged. The size of the region to be ablated is noted. The size of the region to be ablated is compared to a matrix of known ablation regions, each of the known ablation regions being associated with one of the configurations of the particular trocar. The region to be ablated is associated with a most nearly matching known ablation region by comparison of the region to be ablated to the known ablation regions. A trocar is inserted into the uterine fibroid at a position, which more closely matches the position of the particular trocar with respect to the known ablation region. The stylets are deployed from the trocar to an extent corresponding to the configuration. | 03-05-2015 |
Patent application number | Description | Published |
20080228063 | System and method for irradiating a target with electromagnetic radiation to produce a heated region - A system and corresponding method for irradiating a target with electromagnetic radiation to produce a heated region. The system comprises a coupling device operable to couple electromagnetic radiation from a magnetic resonance imaging system. A plurality of energy radiator applicators are connected to the coupling device to receive electromagnetic radiation energy from the coupling device. Each of the radiator applicators is operable to emit a radio frequency heating signal using the electromagnetic radiation energy from the coupling device. A bolus filled with a dielectric fluid is positioned within the inner area of the MRI system. The bolus is operable to receive the radio frequency heating signals from the plurality of energy radiator applicators and direct the radio frequency heating signals into a section of the body to produce a heated region within the body. | 09-18-2008 |
20080319437 | Apparatus and method for selectively heating a deposit in fatty tissue in a body - An apparatus and method for providing hyperthermia treatments to a protruding body portion having fatty tissue surrounding a deposit in the protruding body portion is disclosed. The apparatus includes a cavity for receiving the protruding body portion. A radio frequency antenna array is used to direct a radio frequency signal at a selected frequency into the protruding body portion such as a breast so that the radio frequency signal will have a selected wavelength in the breast to create a circularly polarized radio frequency electromagnetic field to selectively heat the deposit to a temperature greater than the surrounding fatty tissue through resonant heating within the deposit when a diameter of the deposit is within a range of about 0.5 times to 0.16 times the wavelength of the radio frequency signal within the fatty mammary tissue. | 12-25-2008 |
20090306646 | APPARATUS AND METHOD FOR INJECTION ENHANCEMENT OF SELECTIVE HEATING OF A DEPOSIT IN TISSUES IN A BODY - An apparatus and method for providing hyperthermia treatments in a deposit surrounded by tissue in a body is disclosed. A radio frequency antenna array is used to direct a radio frequency signal at a selected frequency into the deposit so that the radio frequency signal will have a selected wavelength in the deposit to selectively heat the deposit to a temperature greater than the surrounding tissue through resonant heating within the deposit. An injectable medium is injected in the deposit to increase a dielectric value and/or conductivity value of the deposit. The injectable medium is selected to increase a specific absorption rate of the radio frequency signal within the deposit relative to the surrounding tissue. | 12-10-2009 |
20100100092 | Apparatus and Method for Selectively Heating a Deposit in Fatty Tissue in a Body - Heat treatment is applied to tissue in need of such treatment which is surrounded by tissue not in need of such treatment, by positioning a deposit within the surrounding tissue adjacent the tissue in need of treatment. The dielectric constant and/or the conductivity of the deposit is greater than that of the surrounding tissue. A radio frequency antenna or antenna array directs a radio frequency signal at a selected frequency into the deposit. The deposit has a diameter within a range of about 0.5 times to about 0.16 times the wavelength of the radio frequency signal within the surrounding tissue. The deposit is heated, at least partially through resonant heating, to a temperature greater than the surrounding tissue to apply heat treatment to the tissue in need of treatment. The deposit may take the form of a balloon of a Mammosite® type device to provide hyperthermia treatment in conjunction with radiation treatment of a breast after a lumpectomy. | 04-22-2010 |
20140012063 | TISSUE HEATING PREDICTION USING FEEDPOINT EM FIELD DETERMINATION - The accuracy of tissue heating in a body when using a phased array hyperthermia system can be improved by using, in conjunction with the hyperthermia system, a program for predicting heating patterns within the tissue based upon a selected E-field value at each of the antenna energy feedpoints. The hyperthermia system includes circuitry necessary to provide information for calculating the complete EM field at each of the antenna feedpoints during treatment, and such calculated actual feedpoint EM fields are feed to the program to be used in place of the otherwise program generated e-fields in predicting the heating pattern produced by the hyperthermia system during treatment. Further initial operating parameters of the hyperthermia system can be set to produce calculated actual EM fields at the antenna feedpoints which approximate the E-field values used by the program in pretreatment optimizing of the heating pattern. | 01-09-2014 |
20160015993 | Apparatus and Method for Creating Small Focus Deep Hyperthermia In Tissue - A radio frequency annular phased array hyperthermia system providing a relatively small heated focal zone in a relatively large tissue mass includes a plurality of radio frequency energy applicators in at least one ring adapted to surround the relatively large tissue mass. A bolus having a dielectric constant is positioned between the energy applicators and the tissue mass. The energy applicators operate at a frequency high enough to create the relatively small heated focal zone. The spacing between adjacent applicators in the at least one ring is less than a critical distance and spacing between adjacent rings when the at least one ring is a plurality of side by side rings is less than a critical distance with such critical distances being interdependent on the frequency of the energy radiated, the dielectric constant of the bolus, the size of the bolus, and the size of the relatively large tissue mass. | 01-21-2016 |
Patent application number | Description | Published |
20090137529 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS - The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB 1) receptor. In particular, compounds of the present invention are 5 prodrugs of antagonists or inverse agonists of the CB 1 receptor. The invention is concerned with the use of these compounds to be converted to compounds that modulate the Cannabinoid-1 (CB 1) receptor. As such, the compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-10 Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. | 05-28-2009 |
20090247499 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS - Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequalae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness. | 10-01-2009 |
20090258884 | Substituted amides - Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. | 10-15-2009 |
20100184758 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 07-22-2010 |
20100184799 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 07-22-2010 |
20120135975 | Substituted Esters as Cannabinoid-1 Receptor Modulators - Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness. | 05-31-2012 |
20120264777 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 10-18-2012 |
20140045746 | ANTIDIABETIC TRICYCLIC COMPOUNDS - Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 02-13-2014 |
20150191495 | ANTIDIABETIC TRICYCLIC COMPOUNDS - Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 07-09-2015 |
20160002255 | ANTIDIABETIC BICYCLIC COMPOUNDS - Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 01-07-2016 |